Immediate side effects study of locally manufactured filgrastim («Leucostim®») in neutropenia treatment and prophylactics in children
Introduction of biosimilars in clinical practice results in substantial reduction of direct medical costs. However, limited data concerning safety and tolerance of biosimilars exist, especially in children. We conducted double blind randomized trial comparing immediate tolerance of locally manufactu...
Saved in:
| Main Authors: | N. Yu. Shipovskaya, E. V. Samochatova, O. B. Polushkina, M. A. Maschan, I. I. Kalinina, A. N. Gracianskay, M. N. Kostileva, A. A. Maschan |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/761 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of filgrastim and polyethylene glycol-filgrastim in the treatment of postchemotherapy neutropenia in children: Phase I clinical trial
by: Saeed Yousofian, et al.
Published: (2019-01-01) -
Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01) -
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
by: Advani S, et al.
Published: (2010-01-01) -
Chemotherapy limiting neutropenia. Is prevention required?
by: I. B. Kononenko, et al.
Published: (2022-01-01) -
Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01)